Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.

Celsa C, Pressiani T, Nishida N, Chamseddine SM, Arvind A, Li M, Fortuny M, Khaled NB, Iavarone M, Toyoda H, Rapposelli IG, Casadei-Gardini A, Vivaldi C, Ulahannan S, Andanamala H, Scheiner B, Pinter M, Orlandi E, Fulgenzi CAM, Manfredi GF, Lombardi P, D'Alessio A, Stefanini B, Villani R, Ponziani FR, Stella L, Carminati O, Ricci AD, Gonzalez M, Sparacino A, Di Maria G, Vaccaro M, Cabibbo G, Cammà C, Reig M, Kelley RK, Singal AG, Kaseb AO, Kudo M, Rimassa L, Pinato DJ

Open source

DOI
10.1016/j.jhepr.2025.101685
Published
2026 Mar
Container
JHEP reports : innovation in hepatology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jhepr.2025.101685,
  title = {Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.},
  author = {Celsa C and Pressiani T and Nishida N and Chamseddine SM and Arvind A and Li M and Fortuny M and Khaled NB and Iavarone M and Toyoda H and Rapposelli IG and Casadei-Gardini A and Vivaldi C and Ulahannan S and Andanamala H and Scheiner B and Pinter M and Orlandi E and Fulgenzi CAM and Manfredi GF and Lombardi P and D'Alessio A and Stefanini B and Villani R and Ponziani FR and Stella L and Carminati O and Ricci AD and Gonzalez M and Sparacino A and Di Maria G and Vaccaro M and Cabibbo G and Cammà C and Reig M and Kelley RK and Singal AG and Kaseb AO and Kudo M and Rimassa L and Pinato DJ},
  year = {2026},
  journal = {JHEP reports : innovation in hepatology},
  doi = {10.1016/j.jhepr.2025.101685},
  url = {https://doi.org/10.1016/j.jhepr.2025.101685}
}

RIS

TY  - JOUR
TI  - Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
AU  - Celsa C
AU  - Pressiani T
AU  - Nishida N
AU  - Chamseddine SM
AU  - Arvind A
AU  - Li M
AU  - Fortuny M
AU  - Khaled NB
AU  - Iavarone M
AU  - Toyoda H
AU  - Rapposelli IG
AU  - Casadei-Gardini A
AU  - Vivaldi C
AU  - Ulahannan S
AU  - Andanamala H
AU  - Scheiner B
AU  - Pinter M
AU  - Orlandi E
AU  - Fulgenzi CAM
AU  - Manfredi GF
AU  - Lombardi P
AU  - D'Alessio A
AU  - Stefanini B
AU  - Villani R
AU  - Ponziani FR
AU  - Stella L
AU  - Carminati O
AU  - Ricci AD
AU  - Gonzalez M
AU  - Sparacino A
AU  - Di Maria G
AU  - Vaccaro M
AU  - Cabibbo G
AU  - Cammà C
AU  - Reig M
AU  - Kelley RK
AU  - Singal AG
AU  - Kaseb AO
AU  - Kudo M
AU  - Rimassa L
AU  - Pinato DJ
PY  - 2026
JO  - JHEP reports : innovation in hepatology
DO  - 10.1016/j.jhepr.2025.101685
UR  - https://doi.org/10.1016/j.jhepr.2025.101685
ER  -

APA

C, C., T, P., N, N., SM, C., A, A., M, L., M, F., NB, K., M, I., H, T., IG, R., A, C., C, V., S, U., H, A., B, S., M, P., E, O., CAM, F., GF, M., P, L., A, D., B, S., R, V., FR, P., L, S., O, C., AD, R., M, G., A, S., G, D. M., M, V., G, C., C, C., M, R., RK, K., AG, S., AO, K., M, K., L, R., & DJ, P. (2026). Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2025.101685

Source records